Search research articles
Contact Us
Filters
Showing results (261-270 of 578) with videos related to
Page
of 58
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 17, 2023
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer
Ingrid Boere, Ignace Vergote, Rob Hanssen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 29, 2022
Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry
Sophie Schoenen, Katty Delbecque, Anne-Sophie Van Rompuy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group
Dirk Timmerman, Antonia C Testa, Tom Bourne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 24, 2012
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data
Stephan Polterauer, Ignace Vergote, Nicole Concin, et al.
The British Journal of Radiology
|
September 3, 2016
Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study
Katrijn L M Michielsen, Ignace Vergote, Raphaëla Dresen, et al.
BMC Pharmacology & Toxicology
|
April 17, 2015
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
Sandrina Lambrechts, Diether Lambrechts, Evelyn Despierre, et al.
Gynecologic Oncology
|
May 18, 2011
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Florence Joly, Isabelle Ray-Coquard, Michel Fabbro, et al.
The Breast Journal
|
November 13, 2010
Additional value of PET-CT in staging of clinical stage IIB and III breast cancer
Isabelle Segaert, Felix Mottaghy, Sarah Ceyssens, et al.
Plos One
|
March 4, 2014
A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples
Melike Marsan, Gert Van den Eynden, Ridha Limame, et al.
Journal of the National Cancer Institute
|
March 18, 2004
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
Gordon J S Rustin, Michael Quinn, Tate Thigpen, et al.
Page
of 58
Search research articles
Search
Showing results (261-270 of 578) with videos related to
Sort By:
Page
of 58
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 17, 2023
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer
Ingrid Boere, Ignace Vergote, Rob Hanssen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 29, 2022
Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry
Sophie Schoenen, Katty Delbecque, Anne-Sophie Van Rompuy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group
Dirk Timmerman, Antonia C Testa, Tom Bourne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 24, 2012
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data
Stephan Polterauer, Ignace Vergote, Nicole Concin, et al.
The British Journal of Radiology
|
September 3, 2016
Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study
Katrijn L M Michielsen, Ignace Vergote, Raphaëla Dresen, et al.
BMC Pharmacology & Toxicology
|
April 17, 2015
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
Sandrina Lambrechts, Diether Lambrechts, Evelyn Despierre, et al.
Gynecologic Oncology
|
May 18, 2011
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Florence Joly, Isabelle Ray-Coquard, Michel Fabbro, et al.
The Breast Journal
|
November 13, 2010
Additional value of PET-CT in staging of clinical stage IIB and III breast cancer
Isabelle Segaert, Felix Mottaghy, Sarah Ceyssens, et al.
Plos One
|
March 4, 2014
A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples
Melike Marsan, Gert Van den Eynden, Ridha Limame, et al.
Journal of the National Cancer Institute
|
March 18, 2004
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
Gordon J S Rustin, Michael Quinn, Tate Thigpen, et al.
Page
of 58